EBMT Handbook 第8版 臨床指引技能
書籍:The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, 8th edition (2024)
編輯:Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E
出版:Springer; Open Access CC BY 4.0
來源:https://www.ncbi.nlm.nih.gov/books/NBK608238/
⚙️ 核心規則(每次回答必須遵守)
- 來源標示:每段落標明
📖 來自 EBMT Handbook 第8版 第 N 章 - 來源區分:
[書中驗證]:內容來自已 fetch 的原書章節[模型補充]:來自 Claude 訓練知識,請交叉核對原文
- 知識截止警告:回答藥物核准、新指引等議題時,加上:
📅 本資訊以 EBMT Handbook 第8版(2024)為準,請確認是否有最新更新。
- 臨床第一:先給出可操作建議,再補充原理
- 計算工具:劑量/評分/CrCl 請執行
scripts/hct_tools.py,每次輸出自帶 safety disclaimer - 死連結保護:若 references/ 中無對應檔案,誠實告知「此章節尚未詳細收錄,請查閱原書」
- 不確定時:明確說明不確定,建議查閱原書 URL:https://www.ncbi.nlm.nih.gov/books/NBK608238/
📚 快速章節路由表
根據問題類型,先查閱對應章節,再深入 references/ 資料夾。
🔍 問題 → 章節 對照
| 問題類型 | 章節 | 深入參考 |
|---|---|---|
| 移植前評估 / 適應症判斷 | Ch.11 | references/part3-methodology.md |
| 捐贈者選擇(成人/兒童) | Ch.12 | references/part3-methodology.md |
| HLA 配對原則 | Ch.9 | references/part2-biological.md ✅ |
| 預處理方案(MAC/RIC/NMA) | Ch.13 | references/part3-methodology.md |
| 幹細胞來源選擇(BM/PB/CB) | Ch.14 | references/part3-methodology.md |
| 骨髓採集 | Ch.15 | references/part3-methodology.md |
| 幹細胞動員與採集 | Ch.16, 17 | references/part3-methodology.md |
| 臍帶血 | Ch.18, 64 | references/part8-modalities.md |
| Graft 處理/冷凍保存 | Ch.19, 20 | references/part3-methodology.md |
| Chimerism 監測 | Ch.21 | references/part3-methodology.md |
| 移植後追蹤 | Ch.22 | references/part3-methodology.md |
| 血管通路(CVC) | Ch.23 | references/part4-management.md |
| 輸血支持 | Ch.24 | references/part4-management.md |
| 營養支持 | Ch.25 | references/part4-management.md |
| GVHD 預防 | Ch.26 | references/part4-management.md |
| 感染控制/隔離 | Ch.27, 28 | references/part4-management.md |
| 疫苗接種 | Ch.29 | references/part4-management.md |
| 心理照護 | Ch.30 | references/part4-management.md |
| 藥物交互作用 | Ch.31 | references/part4-management.md |
| 中性球低燒 | Ch.35 | references/part5-complications.md |
| 細菌感染 | Ch.36 | references/part5-complications.md |
| 黴菌感染 | Ch.37 | references/part5-complications.md |
| 病毒感染(CMV/EBV/HHV6…) | Ch.38 | references/part5-complications.md |
| 其他感染(結核/弓漿蟲) | Ch.39 | references/part5-complications.md |
| 出血/血栓 | Ch.40 | references/part5-complications.md |
| Graft failure | Ch.41 | references/part5-complications.md |
| SOS/VOD(肝竇阻塞症候群) | Ch.49 | references/part6-organ.md |
| 急性 GVHD | Ch.43 | references/part5-complications.md |
| 慢性 GVHD | Ch.44 | references/part5-complications.md |
| PTLD | Ch.45 | references/part5-complications.md |
| 鐵過載 | Ch.46 | references/part5-complications.md |
| 次發性腫瘤 | Ch.47 | references/part5-complications.md |
| 眼/口腔併發症 | Ch.48 | references/part6-organ.md |
| 腸胃道併發症 | Ch.50 | references/part6-organ.md |
| 出血性膀胱炎/腎功能 | Ch.51 | references/part6-organ.md |
| 肺部非感染性併發症 | Ch.52 | references/part6-organ.md |
| 神經系統併發症 | Ch.53 | references/part6-organ.md |
| 皮膚/肌肉骨骼 | Ch.54 | references/part6-organ.md |
| 心血管/代謝症候群 | Ch.55 | references/part6-organ.md |
| 內分泌/生育/性功能 | Ch.56 | references/part6-organ.md |
| MRD 監測 | Ch.57 | references/part7-relapse.md |
| 復發藥物治療(TKI/HMA…) | Ch.58 | references/part7-relapse.md |
| DLI(供者淋巴球輸注) | Ch.59 | references/part7-relapse.md |
| CAR-T / 基因療法 | Ch.60 | references/part7-relapse.md |
| Haploidentical HCT | Ch.65 | references/part8-modalities.md ✅ |
| 老年移植 | Ch.68 | references/part8-modalities.md ✅ |
| AML(成人) | Ch.70 | references/part9-indications.md |
| AML(兒童) | Ch.71 | references/part9-indications.md |
| ALL(成人) | Ch.72 | references/part9-indications.md |
| ALL(兒童) | Ch.73 | references/part9-indications.md |
| MDS | Ch.74, 75 | references/part9-indications.md |
| 骨髓纖維化/CML | Ch.77 | references/part9-indications.md |
| 再生不良性貧血/PNH | Ch.78 | references/part9-indications.md |
| 血色素病變(SCD/Thal) | Ch.80 | references/part9-indications.md |
| 多發性骨髓瘤 | Ch.81 | references/part9-indications.md |
| 淋巴瘤(DLBCL/MCL/iNHL) | Ch.84-88 | references/part9-indications.md |
🧠 臨床決策樹(快速分流)
移植病人問題
├── 移植前?
│ ├── 適應症評估 → Ch.11 + Ch.70-95(疾病別)
│ ├── 捐贈者/來源 → Ch.12, 14, 64, 65
│ └── 預處理選擇 → Ch.13
│
├── 移植中(D-7 到 D+30)?
│ ├── 感染/發燒 → Ch.35, 36, 37, 38
│ ├── 器官毒性 → Ch.42(endothelial), Ch.49(SOS/VOD)
│ ├── GVHD 預防 → Ch.26
│ └── 支持照護 → Ch.23-25, 31
│
├── 移植後早期(D+30 到 D+100)?
│ ├── 急性 GVHD → Ch.43
│ ├── 感染 → Ch.36-39
│ ├── Graft failure → Ch.41
│ └── Chimerism → Ch.21
│
└── 移植後晚期(D+100 之後)?
├── 慢性 GVHD → Ch.44
├── 感染/疫苗 → Ch.29, 38
├── 器官長期併發症 → Ch.48-56
├── MRD/復發 → Ch.57-61
└── 次發腫瘤/生活品質 → Ch.47, 34
🐍 Python 工具使用說明
當問題涉及以下計算時,執行 scripts/hct_tools.py:
| 需求 | 工具函數 |
|---|---|
| BSA(體表面積)計算 | calc_bsa(weight, height) |
| CrCl / eGFR 計算 | calc_crcl(age, weight, creatinine, sex) |
| Sorror HCT-CI 評分 | hct_ci_score(comorbidities_dict) |
| GVHD 分期 | grade_gvhd(skin_pct, bilirubin, stool_vol) |
| 藥物劑量試算 | drug_dose(drug, weight, bsa, renal) |
| Checklist 輸出(JSON) | print_checklist(phase) |
執行方式:python3 /home/claude/ebmt-handbook/scripts/hct_tools.py
📋 常用 Checklist(直接輸出)
移植前評估 Checklist(Ch.11)
{
"phase": "pre-HCT evaluation",
"chapter": 11,
"items": [
{"category": "疾病評估", "tasks": ["疾病分期確認", "MRD 狀態", "細胞遺傳學/分子標記"]},
{"category": "器官功能", "tasks": ["心臟 ECHO(EF>45%)", "肺功能 FEV1/DLCO", "肝功能", "腎功能 CrCl", "神經功能"]},
{"category": "感染篩檢", "tasks": ["CMV IgG", "EBV", "HSV", "VZV", "HIV", "HBV", "HCV", "梅毒", "結核 IGRA"]},
{"category": "HLA 配型", "tasks": ["病患 HLA typing 10/10", "捐贈者搜尋"]},
{"category": "知情同意", "tasks": ["移植風險說明", "生育保存討論", "心理評估"]}
]
}
中性球低燒處理 Checklist(Ch.35)
{
"phase": "febrile neutropenia",
"chapter": 35,
"items": [
{"step": 1, "action": "體溫 >38°C 且 ANC <0.5×10⁹/L → 啟動 FN protocol"},
{"step": 2, "action": "抽血培養 x2(不同部位),含 CVC port"},
{"step": 3, "action": "30分鐘內給予廣效抗生素(pip/tazo 或 cefepime)"},
{"step": 4, "action": "評估是否為 high risk(HCT患者均為 high risk)"},
{"step": 5, "action": "48-72小時仍發燒 → 加上抗黴菌治療"},
{"step": 6, "action": "懷疑 Aspergillus → GM 抗原、胸部 CT"}
]
}
📖 深入閱讀指引
當需要完整的臨床指引內容,請 view 對應 references 檔案:
view /home/claude/ebmt-handbook/references/part2-biological.md # HLA、免疫重建(Ch.7-10)✅新增
view /home/claude/ebmt-handbook/references/part3-methodology.md # 移植方法論(Ch.11-22)
view /home/claude/ebmt-handbook/references/part4-management.md # 一般處置、疫苗(Ch.22-34)
view /home/claude/ebmt-handbook/references/part5-complications.md # GVHD、感染、鐵過載(Ch.35-47)✅擴充
view /home/claude/ebmt-handbook/references/part6-organ.md # 器官併發症(Ch.48-56)✅擴充
view /home/claude/ebmt-handbook/references/part7-relapse.md # 復發/CAR-T(Ch.57-65)
view /home/claude/ebmt-handbook/references/part8-modalities.md # 特殊移植模式(Ch.63-69)✅新增
view /home/claude/ebmt-handbook/references/part9-indications.md # 各疾病+兒童適應症(Ch.70-95)✅擴充
⚠️ 本技能提供臨床參考,不取代個別病人的醫療決策。 所有建議均引用自 EBMT Handbook 第8版(2024),請依據最新機構指引調整。